Epidemiological and Economic Evaluation of a Pilot Prostate Cancer Screening Program

Table 1

Serum PSA levels, free PSA, ProPSA, and PHI in men of Pavlodar region screened for PCa within 2013–2017.

Year	Number of patients examined for PSA	Results of PSA test			Free PSA & ProPSA	PHI 25 and above	Number of identified diseases (N40, N41)	Number of identified PCa
		<3.1 ng/ml	3.1–7.8 ng/ml	>7.8 ng/ml				2–4 points according to Gleason	5–7 points according to Gleason	8–10 points according to Gleason
2013	9888	9504	331	53	129	91	196	8	5	0
2014	11666	11250	320	96	265	200	279	16	6	8
2015	9322	8877	367	78	268	151	355	4	1	2
2016	8821	8426	322	73	188	153	204	4	5	11
2017	9637	9177	339	121	185	142	214	4	6	9
Total	49334	47234	1679	421	1035	737	1248	36	23	30